Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 259

1.

Atypical femoral fractures and bisphosphonate treatment: experience in two large United Kingdom teaching hospitals.

Thompson RN, Phillips JR, McCauley SH, Elliott JR, Moran CG.

J Bone Joint Surg Br. 2012 Mar;94(3):385-90. doi: 10.1302/0301-620X.94B3.27999.

PMID:
22371548
2.

Adherence to oral bisphosphonates and the risk of subtrochanteric and femoral shaft fractures among female medicare beneficiaries.

Wang Z, Ward MM, Chan L, Bhattacharyya T.

Osteoporos Int. 2014 Aug;25(8):2109-16. doi: 10.1007/s00198-014-2738-x. Epub 2014 May 21.

3.

Atypical subtrochanteric and femoral shaft fractures and possible association with bisphosphonates.

Nieves JW, Cosman F.

Curr Osteoporos Rep. 2010 Mar;8(1):34-9. doi: 10.1007/s11914-010-0007-2. Review.

PMID:
20425089
4.

Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study.

Lenart BA, Neviaser AS, Lyman S, Chang CC, Edobor-Osula F, Steele B, van der Meulen MC, Lorich DG, Lane JM.

Osteoporos Int. 2009 Aug;20(8):1353-62. doi: 10.1007/s00198-008-0805-x. Epub 2008 Dec 9.

5.

The outcome of surgically treated femur fractures associated with long-term bisphosphonate use.

Weil YA, Rivkin G, Safran O, Liebergall M, Foldes AJ.

J Trauma. 2011 Jul;71(1):186-90. doi: 10.1097/TA.0b013e31821957e3.

PMID:
21610533
6.

Atypical subtrochanteric femoral fractures in patients with skeletal malignant involvement treated with intravenous bisphosphonates.

Puhaindran ME, Farooki A, Steensma MR, Hameed M, Healey JH, Boland PJ.

J Bone Joint Surg Am. 2011 Jul 6;93(13):1235-42. doi: 10.2106/JBJS.J.01199.

PMID:
21776577
7.

Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort.

Kim SY, Schneeweiss S, Katz JN, Levin R, Solomon DH.

J Bone Miner Res. 2011 May;26(5):993-1001. doi: 10.1002/jbmr.288.

8.

What do we know about atypical femoral fractures? Insights and enigmas.

Audran M, Cortet B, Thomas T; Bone division of the French Society for Rheumatology.

Joint Bone Spine. 2011 Dec;78(6):568-71. doi: 10.1016/j.jbspin.2011.03.015. Epub 2011 May 17. Review.

PMID:
21592839
9.

Atypical femur fractures among breast cancer and multiple myeloma patients receiving intravenous bisphosphonate therapy.

Chang ST, Tenforde AS, Grimsrud CD, O'Ryan FS, Gonzalez JR, Baer DM, Chandra M, Lo JC.

Bone. 2012 Sep;51(3):524-7. doi: 10.1016/j.bone.2012.05.010. Epub 2012 May 23.

PMID:
22634175
10.

Bisphosphonate-associated femur fractures have high complication rates with operative fixation.

Prasarn ML, Ahn J, Helfet DL, Lane JM, Lorich DG.

Clin Orthop Relat Res. 2012 Aug;470(8):2295-301. doi: 10.1007/s11999-012-2412-6. Epub 2012 Jun 6.

11.

Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: sensitivity and trim and fill studies.

Liu J, Zhang HX, Lu XX, Hu JJ, Deng LF.

Genet Test Mol Biomarkers. 2014 Feb;18(2):117-22. doi: 10.1089/gtmb.2013.0331. Epub 2013 Nov 8. Review.

12.

Risk of femoral shaft and subtrochanteric fractures among users of bisphosphonates and raloxifene.

Vestergaard P, Schwartz F, Rejnmark L, Mosekilde L.

Osteoporos Int. 2011 Mar;22(3):993-1001. doi: 10.1007/s00198-010-1512-y. Epub 2010 Dec 17.

PMID:
21165600
13.

[Is SSBT associated with atypical femoral fracture? SSBT isn't associated with atypical femoral fracture].

Soen S.

Clin Calcium. 2012 Jun;22(6):919-22. doi: CliCa1206919922. Japanese.

PMID:
22653034
14.

Atypical femoral fractures after anti-osteoporotic medication: a Korean multicenter study.

Kang JS, Won YY, Kim JO, Min BW, Lee KH, Park KK, Song JH, Kim YT, Kim GH.

Int Orthop. 2014 Jun;38(6):1247-53. doi: 10.1007/s00264-013-2259-9. Epub 2014 Jan 25.

15.

Association of atypical femoral fractures with bisphosphonate use by patients with varus hip geometry.

Hagen JE, Miller AN, Ott SM, Gardner M, Morshed S, Jeray K, Alton TB, Ren D, Abblitt WP, Krieg JC.

J Bone Joint Surg Am. 2014 Nov 19;96(22):1905-9. doi: 10.2106/JBJS.N.00075.

PMID:
25410509
16.

Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur.

Black DM, Kelly MP, Genant HK, Palermo L, Eastell R, Bucci-Rechtweg C, Cauley J, Leung PC, Boonen S, Santora A, de Papp A, Bauer DC; Fracture Intervention Trial Steering Committee; HORIZON Pivotal Fracture Trial Steering Committee.

N Engl J Med. 2010 May 13;362(19):1761-71. doi: 10.1056/NEJMoa1001086. Epub 2010 Mar 24.

17.

[Atypical femoral fracture associated with the use of bisphosphonates, an adverse drug reaction not to be missed].

Ing Lorenzinit K, Meier R, Suva D, Dayer P, Desmeules J, Peter R.

Rev Med Suisse. 2012 Jun 6;8(344):1238-42. Review. French.

PMID:
22730621
18.

Bisphosphonates and hip and nontraumatic subtrochanteric femoral fractures in the Veterans Health Administration.

Safford MM, Barasch A, Curtis JR, Outman R, Saag K.

J Clin Rheumatol. 2014 Oct;20(7):357-62. doi: 10.1097/RHU.0000000000000170.

PMID:
25275761
19.

Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases.

Pazianas M, Abrahamsen B, Wang Y, Russell RG.

Osteoporos Int. 2012 Dec;23(12):2873-84. doi: 10.1007/s00198-012-1952-7. Epub 2012 Mar 20.

PMID:
22431012
20.

Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women.

Park-Wyllie LY, Mamdani MM, Juurlink DN, Hawker GA, Gunraj N, Austin PC, Whelan DB, Weiler PJ, Laupacis A.

JAMA. 2011 Feb 23;305(8):783-9. doi: 10.1001/jama.2011.190.

PMID:
21343577

Supplemental Content

Support Center